BUSINESS
Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo
Daiichi Sankyo said on August 26 that the National Institute for Health and Care Excellence (NICE) has issued a final recommendation for the use of its anticoagulant Lixiana (edoxaban) under the National Health Service in the UK. The NICE recommendation…
To read the full story
Related Article
- NICE Recommends New Lixiana Indication for Health Coverage: Daiichi Sankyo
September 25, 2015
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





